Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Hand and Shoulder Function in Children following Early Surgical Intervention for a Birth-Related Upper Brachial Plexus Injury.

Journal of brachial plexus and peripheral nerve injury·2024
Same author

Four Anchor Repair of Jersey Finger.

The Iowa orthopaedic journal·2021
Same author

[Updating pediatric neurology VI. XXXI Curso Postgrado y XXVII Congreso de la Academia Iberoamericana de Neurología Pediátrica. Introduction].

Medicina·2019
Same author

[Predominant factors of neonatal encephalopathy: hypoxic and ischemia, a global problem].

Medicina·2019
Same author

[Updating pediatric neurology V. Introduction].

Medicina·2018
Same author

[Neonatal hypoxic-ischemic encephalopathy].

Medicina·2018

Related Experiment Video

Updated: Jun 25, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

[Juvenile myasthenia gravis].

Oscar Papazian1, Israel Alfonso

  • 1Departamento de Neurología, Miami Children's Hospital, Miami FL, USA. Oscar.Papazian@mch.com

Medicina
|February 26, 2009
PubMed
Summary
This summary is machine-generated.

Juvenile myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission due to antibodies targeting acetylcholine receptors. Diagnosis involves clinical signs, nerve stimulation, and antibody tests, with treatments including symptomatic and immunosuppressive therapies.

Related Experiment Videos

Last Updated: Jun 25, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Disorders

Context:

  • Juvenile myasthenia gravis (JMG) is a rare, chronic autoimmune neuromuscular disease.
  • It arises from antibodies attacking nicotinic acetylcholine receptors at the motor endplate.
  • This impairs neuromuscular transmission, leading to muscle fatigability and paralysis.

Purpose:

  • To provide a comprehensive overview of juvenile myasthenia gravis.
  • To detail its pathophysiology, clinical presentation, diagnostic methods, and treatment strategies.
  • To highlight the importance of early diagnosis and management in children.

Summary:

  • JMG involves serum antibodies binding to nicotinic acetylcholine receptors, disrupting neuromuscular transmission.
  • Clinical manifestations include muscle fatigability, progressing to paralysis, with cranial nerves often affected.
  • Diagnosis is supported by history, physical exam, nerve stimulation studies, response to acetylcholinesterase inhibitors, and presence of acetylcholine receptor antibodies (ACRA).

Impact:

  • Understanding JMG aids in timely diagnosis and appropriate management, improving patient outcomes.
  • Current treatments include symptomatic (acetylcholinesterase inhibitors) and etiological therapies (immunosuppressants, plasmapheresis, IVIg, thymectomy).
  • While remissions occur, children face risks during myasthenic crisis, underscoring the need for vigilant care.